



	Dr. Vinay Ch MD (Pathology & Chairman & Con	Microbiology)	Dr. Yugam MD & Consultant	(Pathology)
NAME	: Mr. VICKY BHATIA			
AGE/ GENDER	: 44 YRS/MALE	PATIENT II)	: 1667834
COLLECTED BY	:	REG. NO./L	AB NO.	: 012411110005
REFERRED BY	:	REGISTRAT	TION DATE	: 11/Nov/2024 08:11 AM
BARCODE NO.	: 01520533	COLLECTIO	N DATE	: 11/Nov/2024 08:17AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING	G DATE	: 11/Nov/2024 10:52AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,	AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
	CLINIC	CAL CHEMISTRY/BIO	CHEMIST	'RY
		LIPID PROFILE : BA		
CHOLESTEROL TOT by CHOLESTEROL OX		223.66 ^H	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0
TRIGLYCERIDES: SI by GLYCEROL PHOSP	ERUM HATE OXIDASE (ENZYMATIC)	419.41 ^H	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTEROI	L (DIRECT): SERUM	41.7	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTEROI by CALCULATED, SPE		NOT CALCULATED	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLEST by calculated, spe		181.96 ^H	mg/dL	VERY HIGH: > OR = 190.0 OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTERO		NOT CALCULATED	mg/dL	0.00 - 45.00
by CALCULATED, SPE TOTAL LIPIDS: SER	UM	NOT CALCULATED	mg/dL	350.00 - 700.00
by CALCULATED, SPE CHOLESTEROL/HD by CALCULATED, SPE	L RATIO: SERUM	5.36 ^H	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





	Dr. Vinay Ch MD (Pathology & Chairman & Con	Microbiology)	Dr. Yugam MD & Consultant	(Pathology)
NAME : N	Mr. VICKY BHATIA			
AGE/ GENDER : 4	44 YRS/MALE	PATIENT ID)	: 1667834
COLLECTED BY :		REG. NO./L/	AB NO.	: 012411110005
REFERRED BY :		REGISTRAT	TION DATE	: 11/Nov/2024 08:11 AM
BARCODE NO. : 0	01520533	COLLECTIO	N DATE	: 11/Nov/2024 08:17AM
	KOS DIAGNOSTIC LAB	REPORTING	G DATE	: 11/Nov/2024 10:52AM
CLIENT CODE. : ł	KUS DIAGNUSTIC LAB	NEI ONTIN		
CLIENT ADDRESS : 6	6349/1, NICHOLSON ROAD,	AMBALA CANTT	Unit	Biological Reference interval
CLIENT ADDRESS : 6	6349/1, NICHOLSON ROAD,			Biological Reference interval MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
CLIENT ADDRESS : 6 Test Name LDL/HDL RATIO: SERU	6349/1, NICHOLSON ROAD, UM корнотометку RATIO: SERUM	AMBALA CANTT	Unit	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0
CLIENT ADDRESS : (Test Name LDL/HDL RATIO: SERU by CALCULATED, SPECTR FRIGLYCERIDES/HDL	6349/1, NICHOLSON ROAD, UM корнотометку RATIO: SERUM	AMBALA CANTT Value NOT CALCULATED 10.06 ^H	Unit RATIO RATIO ES VALUE >4	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0 3.00 - 5.00

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

 Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
 NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

*** End Of Report





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com

